P1087: Favezelimab (Anti–lag-3) and Pembrolizumab Co-Blockade in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Who Progressed After Anti–pd-1 Therapy: An Open-Label Phase 1/2 Study

Herrera, Alex F.; Lavie, David; Johnson, Nathalie A.; Avigdor, Abraham; Borchmann, P.; Andreadis, Charambalos; Bazargan, Ali; Gregory, Gareth P.; Keane, Colm; Tzoran, Inna; Vucinic, V.; Zinzani, P. L.; Zhang, H.; Pillai, Pallavi; Marinello, Patricia; Timmerman, John M.

doi:10.1097/01.hs9.0000847216.85071.f3

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 13 Inhibition of LAG-3 has shown the capability to restore cytotoxic activity in exhausted T cells and reduce regulating T cells’ immune suppression function, thereby enhancing the killing effect on tumors. 14 Although the anti-LAG-3 antibody relatlimab has been approved in combination with nivolumab for patients with advanced melanoma, 15 clinical trials are ongoing in patients with classical Hodgkin lymphoma 16 , 17 and other indications, 18 and prospective studies would be needed to evaluate the benefit of anti-LAG3 therapies in patients with FL.…”

Section: Discussionmentioning

confidence: 99%

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Dreyling,

Fowler,

Dickinson

et al. 2024

Blood

View full text Add to dashboard Cite

Tisagenlecleucel is approved for adults with relapsed/refractory (r/r) follicular lymphoma (FL) in the ≥3rd-line setting. The primary analysis (median follow-up: 17 months) of the Phase II ELARA trial (ClinicalTrials.gov identifier: NCT03568461) reported high response rates and excellent safety profile in extensively pretreated patients with r/r FL. Here we report longer-term efficacy, safety, pharmacokinetic, and exploratory biomarker analyses after a median follow-up of 29 months. As of March 29, 2022, 97 patients with r/r FL (grades 1-3A) after ≥2 lines of therapy or who relapsed after autologous stem cell transplant received tisagenlecleucel infusion (0.6-6×108 CAR+ viable T cells). Bridging chemotherapy was allowed. Baseline clinical factors, tumor microenvironment (TME), blood soluble factors, and circulating blood cells were correlated with clinical response. Cellular kinetics were assessed by quantitative polymerase chain reaction. Median progression-free survival (PFS), duration of response (DOR), and overall survival (OS) were not reached after 29 months median follow-up (IQR, 22.2-37.7). Estimated 24-month PFS, DOR, and OS rates in all patients were 57.4% (95% CI, 46.2-67), 66.4% (95% CI, 54.3-76), and 87.7% (95% CI, 78.3-93.2). Complete response rate and overall response rate were 68.1% (95% CI, 57.7-77.3) and 86.2% (95% CI, 77.5-92.4), respectively. No new safety signals or treatment-related deaths were reported. Low levels of tumor-infiltrating LAG3+CD3+ exhausted T-cells and higher baseline levels of naïve CD8+ T-cells were associated with improved outcomes. Tisagenlecleucel continued to demonstrate highly durable efficacy and a favorable safety profile in this extended follow-up of 29 months in patients with r/r FL enrolled in ELARA.

show abstract